Galway, 25th November 2022 –OmniSpirant Limited and EVerZom are delighted and honoured to announce the launch of INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant in collaboration with our European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy, are already actively working on the project deliverables, and recently met in Galway, Ireland for the official kick-off meeting (see the picture below taken on the 28th October 2022). [Read more…]
Brexogen’s Exosome Therapy for Atopic Dermatitis, ‘BRE-AD01’ Accepted for Phase 1 Clinical Trials by US FDA
First entry to clinical trial of exosome for atopic dermatitis and the first exosome-based therapeutics in US clinical trial among Korean companies
SEOUL, South Korea I November 2, 2022 – The US FDA granted the initiation of the phase 1 clinical trial of ‘BRE-AD01’, an exosome- based therapy for atopic dermatitis. ‘BRE-AD01’ is being developed by Brexogen with its own exosome-platform technology. It is the first phase 1 clinical trial of therapeutic exosome for atopic dermatitis in major countries. This IND clearance is very meaningful in that patients with atopic dermatitis can benefit from receiving better treatment with ‘BRE-AD01’, which is armed with multiple mode of action. [Read more…]
Approved Exosome Diagnostics: ExoDx Prostate IntelliScore & Guardant360 CDx
While solid biopsies have several limitations, including but not limited to their invasive nature, liquid biopsies can offer a promising alternative. Today, a growing number of companies are developing exosome diagnostics for the non-invasive detection and prognosis of cancer and other serious medical conditions. This approach is effective because exosomes are present in almost all body fluids and critical valuable information about the cells from which they were released. [Read more…]
Americord® Releases Exosomes Banking with CryoMaxx™ Processing
Americord Registry announces the addition of exosome banking to their suite services, becoming the first company in the United States to do so.
NEW YORK, NEW YORK, US, October 11, 2022 – Americord Registry®, a leader in the cord blood industry, announced the addition of exosome banking to their suite of family-focused services, becoming the first private biobanking company in the United States to do so. Exosomes are tiny, extracellular vesicles that initiate cell-to-cell communication by shuttling cellular components to other cells. Pre-clinical research has shown that exosomes may regulate immune responses, wound healing, and cell growth and development. [Read more…]
Exosome Industry Progress is Accelerated by Landmark Events (Timeline)
Exosomes are small vesicles that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. It has been long known that stem cells have the potential to exert therapeutic effects, but it only now being recognized that exosomes play an important role how these effects occur.
Over the past few years, this recognition has fueled a market for products and technologies leveraging stem cell exosomes. Key events in the formation of this market are highlighted in the timeline below. [Read more…]
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 27
- Next Page »